CD47 blockade has shown promising activity in patients with advanced hematologic cancers22, and clinical trials are currently being designed to evaluate whether CD47 inhibition enhances the activity of other immunotherapies in osteosarcoma patients18. This evidence concerns the gene CD47 and osteosarcoma.